argenx (ARGX) Expected to Announce Quarterly Earnings on Thursday

argenx (NASDAQ:ARGX) will likely be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect argenx to post earnings of $0.98 per share and revenue of $678.52 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

argenx Stock Down 0.2 %

ARGX stock opened at $624.94 on Wednesday. The company has a market cap of $37.97 billion, a PE ratio of -710.16 and a beta of 0.58. The business has a 50-day simple moving average of $642.66 and a 200 day simple moving average of $589.24. argenx has a 52 week low of $349.86 and a 52 week high of $678.21.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $717.00 price target (up previously from $670.00) on shares of argenx in a research note on Tuesday, January 14th. Wells Fargo & Company boosted their price target on argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. Robert W. Baird downgraded argenx from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. JPMorgan Chase & Co. boosted their target price on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Finally, Evercore ISI boosted their target price on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.